D.A. Davidson & CO. Sells 292 Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC)

D.A. Davidson & CO. lessened its position in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 5.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,722 shares of the company’s stock after selling 292 shares during the period. D.A. Davidson & CO.’s holdings in GE HealthCare Technologies were worth $443,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of the company. LGT Financial Advisors LLC raised its stake in GE HealthCare Technologies by 1,673.3% during the 3rd quarter. LGT Financial Advisors LLC now owns 266 shares of the company’s stock worth $25,000 after buying an additional 251 shares during the period. Fred Alger Management LLC bought a new position in shares of GE HealthCare Technologies during the 2nd quarter valued at about $26,000. Capital Performance Advisors LLP acquired a new position in shares of GE HealthCare Technologies in the 3rd quarter valued at approximately $26,000. Ashton Thomas Securities LLC bought a new stake in GE HealthCare Technologies during the 3rd quarter worth approximately $26,000. Finally, Elkhorn Partners Limited Partnership acquired a new stake in GE HealthCare Technologies during the 2nd quarter worth approximately $31,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

GE HealthCare Technologies Trading Down 0.6 %

Shares of NASDAQ:GEHC opened at $82.57 on Wednesday. The business’s 50 day simple moving average is $87.62 and its 200 day simple moving average is $83.67. GE HealthCare Technologies Inc. has a 1 year low of $67.00 and a 1 year high of $94.55. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.23 and a quick ratio of 0.98. The company has a market capitalization of $37.72 billion, a P/E ratio of 22.68, a P/E/G ratio of 2.97 and a beta of 1.07.

GE HealthCare Technologies (NASDAQ:GEHC) last released its earnings results on Wednesday, October 30th. The company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.06 by $0.08. The company had revenue of $4.86 billion for the quarter, compared to analyst estimates of $4.87 billion. GE HealthCare Technologies had a return on equity of 25.19% and a net margin of 8.56%. GE HealthCare Technologies’s quarterly revenue was up .9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.99 EPS. On average, research analysts anticipate that GE HealthCare Technologies Inc. will post 4.3 EPS for the current fiscal year.

GE HealthCare Technologies Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Tuesday, January 14th will be given a $0.035 dividend. The ex-dividend date is Tuesday, January 14th. This is a boost from GE HealthCare Technologies’s previous quarterly dividend of $0.03. This represents a $0.14 annualized dividend and a dividend yield of 0.17%. GE HealthCare Technologies’s payout ratio is presently 3.30%.

Insider Transactions at GE HealthCare Technologies

In other GE HealthCare Technologies news, CEO Roland Rott sold 3,577 shares of the company’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $86.48, for a total transaction of $309,338.96. Following the completion of the sale, the chief executive officer now directly owns 24,298 shares in the company, valued at $2,101,291.04. This represents a 12.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.27% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on GEHC. BTIG Research upgraded shares of GE HealthCare Technologies from a “neutral” rating to a “buy” rating and set a $100.00 price target for the company in a report on Wednesday, September 18th. Evercore ISI upped their price objective on GE HealthCare Technologies from $98.00 to $102.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. JPMorgan Chase & Co. assumed coverage on GE HealthCare Technologies in a research note on Monday, September 9th. They issued a “neutral” rating and a $90.00 price target on the stock. Wells Fargo & Company lifted their price objective on shares of GE HealthCare Technologies from $95.00 to $96.00 and gave the stock an “overweight” rating in a research report on Thursday, October 31st. Finally, UBS Group lowered shares of GE HealthCare Technologies from a “neutral” rating to a “sell” rating and dropped their price objective for the company from $84.00 to $74.00 in a research report on Thursday, September 26th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $95.46.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.